Several genetic mutations have been
identified in patients with CLL
that can influence the disease course
and their response to treatments.
Some of the commonly noted mutations in
CLL are TP53
This mutations associated
with poor prognosis in patients with CLL
typically, a shorter time to starting
therapy, as well as inferior
response to certain types of therapies
in CLL.
ATM gene deletion is another
gene mutation that is noted in CLL
and that's been associated with adverse
prognoses as well as resistance
to certain types of therapies.
NOTCH1 is another mutation
that is associated with poor prognosis,
adverse disease, as well as resistance
to certain therapies,
namely chemotherapy in patients with CLL
SF3B1 is another
gene mutation that can be sometimes
associated with indolent disease.
This is another gene mutation
that can be identified
through our next generation
sequencing techniques.
These are just some of the gene mutations
that are noted in CLL
and can be diagnosed
by our FISH as well as of next generation
sequencing techniques.
However, it is important to know that patients
may not have any of these gene mutations
and there are other patients
who have other gene mutations that are not
noted in this list.
HealthTree • January 9, 2024